BRIEF-Travere Therapeutics Enters Into Exclusive Licensing Agreement With Everest Medicines For Civorebrutinib A Potential Best-In-Class Btk Inhibitor For Rare Kidney Diseases

Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

TVTX

0.00

June 2 (Reuters) - Travere Therapeutics Inc TVTX.O:

  • TRAVERE THERAPEUTICS ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH EVEREST MEDICINES FOR CIVOREBRUTINIB A POTENTIAL BEST-IN-CLASS BTK INHIBITOR FOR RARE KIDNEY DISEASES

  • TRAVERE THERAPEUTICS - EVEREST TO RECEIVE $112.5 MILLION UPFRONT FOR CIVOREBRUTINIB RIGHTS

  • TRAVERE THERAPEUTICS - EVEREST ELIGIBLE FOR UP TO $1.03 BILLION IN ADDITIONAL MILESTONE PAYMENTS

  • TRAVERE THERAPEUTICS - TO PAY TIERED ROYALTIES ON FUTURE CIVOREBRUTINIB SALES

Source text: ID:nBw54m8N0a

Further company coverage: TVTX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.